The Joint stock fell 1.04 percent as Texas rights reshape growth

Published on 10/07/2026 at 06:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The Joint stock regained Texas development rights linked to more than 150 clinic opportunities on October 6, 2026. Q2 revenue rose 14.4 percent year over year.

JYNT, US47973J1025, Illustration mit AI erstellt.

The Joint stock (ISIN US47973J1025) fell 1.04 percent to USD 7.11 on Nasdaq on October 6, 2026, as the company announced a wider territory strategy. The Texas reacquisition gives The Joint direct control over development rights tied to more than 150 potential clinics across several markets.

Texas rights expand clinic potential

According to FT on October 6, 2026, The Joint reacquired regional developer rights across Dallas, Austin, San Antonio and Houston. The company said the transaction follows similar territory reacquisitions in Chicago, Minnesota, Ohio and Nebraska.

The reacquired markets represent potential for more than 150 additional clinics, while regional developers' share of the system unit count fell from 52 percent at the start of 2026 to 32 percent after the territory transactions. That shift gives The Joint greater direct influence over franchisee support and future clinic development, but the clinic figure describes development potential rather than completed openings.

Revenue comparison supports the strategy

According to Markets Insider, second-quarter 2026 revenue was USD 15.18 million, compared with USD 13.27 million in the second quarter of 2025. The USD 1.91 million increase equals 14.4 percent and gives the territory strategy a measurable operating backdrop.

The same October 2, 2026 report said analyst consensus was Moderate Buy with an average price target of USD 10.50. Roth MKM analyst George Kelly reiterated a Buy rating and set a USD 12.00 target, according to Markets Insider on October 2, 2026.

Stock stays below yearly high

The Joint stock was last at USD 7.11 on Nasdaq on October 6, 2026, after a prior close of USD 7.18. The session range was USD 7.05 to USD 7.25, volume was 100,577 shares and the 52-week range was USD 7.04 to USD 10.67.

The average analyst target of USD 10.50 lies 47.7 percent above the October 6 price. The market capitalization stood at USD 101.4 million on that date, leaving the territory strategy and quarterly revenue growth as the main company-specific measures behind the valuation.